C-Suite Snippets: Medtech Leaders

For months, US Health and Human Services Secretary Robert F. Kennedy Jr. had talked about banning direct-to-consumer television ads for prescription drugs. And now, he is making good on his promise – but in a roundabout way.

Early commercial successes are proving the value of digital twins, yet regulatory uncertainty and cultural resistance continue to limit widespread uptake across biopharma.

The gap between investor returns and patient returns is precisely that which the SALY/SADY framework is designed to fill.

Charles River's chief scientific officer Julie Frearson discusses how the agency's embrace of artificial intelligence is driving a fundamental shift in how companies must structure and manage their research data